



## ASX ANNOUNCEMENT

6 MARCH 2018

### RECEIPT OF IMPORT PERMITS FOR GENETICS AND CANNABIS OIL

---

- **Tissue culture to be imported from partners Aurora Cannabis & Anandia Labs**
- **Broadens Cann's bank of genetics & cultivation capability**
- **Four cannabis oil products developed by Aurora Cannabis to be imported for use by Australian patients**

**6 March 2018** – Cann Group Limited (ASX: CAN) has been granted import permits by the drug control section of the Therapeutic Goods Administration (TGA) that enables the company to commence the import of genetics and cannabis oils from its Canadian partners.

The receipt of the genetics import permits will see Cann begin importing tissue culture from Aurora Cannabis and Anandia Labs, which will be used to develop mother plants for Cann's cultivation activities.

The importation of these genetics will allow Cann to establish a bank of various genetics, therefore facilitating research into the suitability of each genetic strain for certain therapeutic applications.

In addition, by fostering a plant breeding program Cann will establish surety around the supply of material moving forward and broaden this supply beyond locally available gene banks.

Cann Group has immediately commenced the process to import the tissue culture, which will be received in the coming weeks pending a quarantine screening process conducted by the Department of Agriculture and Water Resources.

The import permits for cannabis oil will allow Cann to bring four products developed by Aurora Cannabis to Australia, which will be made available to medical practitioners seeking to provide medicinal cannabis to patients under the Special Access Scheme or Authorised Prescriber Scheme.

In respect of both sets of permits, the corresponding export permits from Health Canada have also been secured.

Cann Group CEO Peter Crock said working closely with quality Canadian partners enables the Company to more quickly advance its own development.

"With these genetics we will broaden our genetic base and improve our ability to cultivate various strains of medicinal cannabis," he said.

“In addition to this, we are serious about providing access to product for Australian patients as quickly and easily as is possible, and the importation of oils fast-tracks this while we develop our own capabilities and products within Australia.”

**For further information please contact:**

Peter Crock  
Cann Group Limited  
+61 (0) 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Matthew Wright  
NWR Communications  
+61 (0) 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**About Cann Group**

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia and internationally (once exports are permitted). The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.